# Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)

> **NCT02338570** · PHASE4 · TERMINATED · sponsor: **Mario Negri Institute for Pharmacological Research** · enrollment: 31 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT02338570
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07
- **Primary completion:** 2018-02
- **Final completion:** 2018-02
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Stopped on November 16th 2016, because of recruitment failure.
- **Last updated:** 2018-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02338570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02338570, "Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02338570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*